Paratek Pharmaceuticals, Inc. (PRTK): Price and Financial Metrics
PRTK Price/Volume Stats
Current price | $2.23 | 52-week high | $3.65 |
Prev. close | $2.19 | 52-week low | $1.29 |
Day low | $2.19 | Volume | 4,764,400 |
Day high | $2.24 | Avg. volume | 724,253 |
50-day MA | $2.20 | Dividend yield | N/A |
200-day MA | $2.06 | Market Cap | 127.83M |
PRTK Stock Price Chart Interactive Chart >
Paratek Pharmaceuticals, Inc. (PRTK) Company Bio
Paratek Pharmaceuticals focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. The company was founded in 1996 and is based in in Boston, Massachusetts.
Latest PRTK News From Around the Web
Below are the latest news stories about PARATEK PHARMACEUTICALS INC that investors may wish to consider to help them evaluate PRTK as an investment opportunity.
Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Gurnet Point Capital (“Gurnet Point”) and Novo Holdings A/S (“Novo Holdings”) announced today the completion of their acquisition of Paratek Pharmaceuticals, Inc. (“Paratek” or the “Company”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats. The Company's lead commercial product, NUZYRA® (omadacycline), |
Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) is definitely on the radar of institutional investors who own 48% of the companyKey Insights Significantly high institutional ownership implies Paratek Pharmaceuticals' stock price is sensitive to... |
Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and Novo Holdings A/SBOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (“Paratek”) (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced, based on a preliminary vote count, that stockholders have approved the merger agreement proposal at Paratek’s special meeting of stockholders, in connection with the previously announced definitive agreemen |
Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo Holdings A/SFollows the recommendation from ISS to vote FOR the transactionBOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that a second leading independent proxy advisor Glass, Lewis & Co. (“Glass Lewis”) has recommended that stockholders vote FOR the Company's prev |
Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR the Acquisition by Gurnet Point Capital and Novo HoldingsBOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. ("Paratek") (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel therapies for life-threatening diseases and other public health threats, today announced that leading independent proxy advisor Institutional Shareholder Services Inc. (“ISS”) has recommended that stockholders vote FOR the Company's previously announced definitive agreement to be acquired by Gur |
PRTK Price Returns
1-mo | N/A |
3-mo | N/A |
6-mo | N/A |
1-year | 14.36% |
3-year | -68.01% |
5-year | -58.40% |
YTD | N/A |
2023 | 0.00% |
2022 | -58.35% |
2021 | -28.27% |
2020 | 55.33% |
2019 | -21.44% |
Continue Researching PRTK
Want to do more research on Paratek Pharmaceuticals Inc's stock and its price? Try the links below:Paratek Pharmaceuticals Inc (PRTK) Stock Price | Nasdaq
Paratek Pharmaceuticals Inc (PRTK) Stock Quote, History and News - Yahoo Finance
Paratek Pharmaceuticals Inc (PRTK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...